Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by fishtailon Oct 05, 2020 11:32am
230 Views
Post# 31666739

Resverlogix spinout inks R&D deal with cancer institute

Resverlogix spinout inks R&D deal with cancer institute

Resverlogix spinout inks R&D deal with cancer institute


2020-10-05 08:56 ET - News Release

 

Mr. Donald McCaffrey reports

ZENITH EPIGENETICS ANNOUNCES COLLABORATION WITH NCI IN DEVELOPING ZEN-3694 FOR MULTIPLE ONCOLOGY INDICATIONS

Resverlogix Corp. spinout Zenith Epigenetics Ltd. has executed a co-operative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith's epigenetic therapy {ˠ –} BET inhibitor ZEN-3694 {̂ –} with immuno-oncology therapies {̬ –} checkpoint inhibitors nivolumab and ipilimumab {ͦ –} in resistant ovarian cancer.

"This significant research and development agreement allows us to leverage the combined resources of the NCI, Zenith, and other pharmaceutical companies to develop ZEN-3694 in multiple oncology indications with significant unmet need," said Donald McCaffrey, President and CEO of Zenith. "NCI's interest validates our belief that ZEN-3694 is a leading and differentiated BET inhibitor.

"Our therapy has proven to be safe and effective in prostate and breast cancer treatment and is combinable with multiple targeted agents. This collaboration will significantly supplement our efforts in expanding the portfolio of indications for ZEN-3694 both as a single agent and as a component of novel combination regimens with other therapies. We expect to announce other novel clinical trials including molecular pre-selection concepts in collaboration with the NCI in the upcoming months based on the high level of interest from leading key opinion leaders and clinical researchers."

Bullboard Posts